We’re pleased to share that our methodological work on variable selection with random forests has now been published in BMC Bioinformatics. The paper introduces shadowVIMP, a novel variable selection method based on random forest importance measures and...
We are pleased that part of our work got published as a scientific article in the International Journal of Molecular Sciences on November 7th, 2025. In this publication, we supported the bioinformatic analysis in a study investigating the effect of Vicadrostat...
We are pleased that part of our work has been published as a letter to the author in the Journal of investigative dermatology. In this publication we supported the bioinformatic analysis in a study investigating the effect of spesolimab on microRNA expression in...
At Staburo, we’re committed to developing solutions to statistical challenges that go beyond standard methods – supporting both client projects and scientific progress. A recent example of this commitment is shadowVIMP, a novel variable selection method...
At Staburo, we’re continuously improving the quality and efficiency of our statistical programming workflows. As part of this commitment, we have successfully integrated Git as a version control system into our established folder structure. This step...
Under the umbrella of our Staburo strategy 2027, we identified important topics for our industry and our company. Accordingly, a number of internal strategic initiatives, in which team members jointly work on these topics, were launched. At the end of 2023, five...
As we step into a new year, here’s a recap of key highlights from 2024 in the field of biomarkers at Staburo. June: At the PSI conference in Amsterdam, biomarkers were the focus of a dedicated session, followed by an in-person meeting of the PSI/EFSPI Biomarker...
We are proud to announce that on November 7th, 2024, our director of biostatistics in the focus area biomarkers, Laura Schlieker delivered gave an insightful presentation on “Deep Learning in Image Analysis” at the PSI/EFSPI Biomarkers Special Interest Group (SIG) within the Machine Learning (ML) substream.
Based on the current EU corporate sustainability reporting directive (CSRD) Staburo currently takes a closer look on how our ESG (environmental, social and governance) actions affect our business. We are delighted that our current working student Alkida Hoxhaj and her fellow student Gledis Zhugli from Technical University München (TUM) support Staburo within this field.
The event featured several talks and a poster session. Invited speakers included Torsten Hothorn from the University of Zurich, who presented a tutorial on “A transformation perspective on Survival Analysis”; Torben Martinussen from the University of Copenhagen, who discussed “Subtleties in the interpretation of hazard ratios”; and Jan Feifel from Merck Healthcare KGaA, who spoke about “Real world evidence supporting clinical development in Oncology”.
The study was the largest prospective study to date assessing the combination of anti-programmed cell death protein 1 (PD-1) antibodies and multikinase inhibitors. This combination has shown encouraging activity in several tumour types, including colorectal cancer. In this study, 5 of 70 treated patients had a partial response, corresponding to an objective response rate of 7%.
Hannes Buchner, Staburo Managing Director, along with working students Maria Blanco and Tim Müller, will present their applied research project titled “Deriving interpretable thresholds for variable importance in random forests by permutation” at the colloquium of the Statistics Institute at the Ludwig-Maximilians-Universität (LMU) on May 10th at 16:00.